Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer

Zhen Su, Jens Dannull, Benjamin K. Yang, Philipp Dahm, Doris Coleman, Donna Yancey, Sylvia Sichi, Donna Niedzwiecki, David Boczkowski, Eli Gilboa, Johannes Vieweg

Research output: Contribution to journalArticle

263 Citations (Scopus)

Abstract

Telomerase reverse transcriptase (hTERT) represents an attractive target for cancer immunotherapy because hTERT is reactivated in most human tumors. A clinical trial was initiated in which hTERT mRNA-transfected dendritic cells (DC) were administered to 20 patients with metastatic prostate cancer. Nine of these subjects received DC transfected with mRNA encoding a chimeric lysosome-associated membrane protein-1 (LAMP) hTERT protein, allowing for concomitant induction of hTERT-specific CD8+ and CD4+ T cell responses. Treatment was well tolerated. Intense infiltrates of hTERT-specific T cells were noted at intradermal injection sites after repeated vaccination. In 19 of 20 subjects, expansion of hTERT-specific CD8+ T cells was measured in the peripheral blood of study subjects, with 0.9-1.8% of CD8+ T cells exhibiting Ag specificity. Patients immunized with the chimeric LAMP hTERT vaccine developed significantly higher frequencies of hTERT-specific CD4+ T cells than subjects receiving DC transfected with the unmodified hTERT template. Moreover, CTL-mediated killing of hTERT targets was enhanced in the LAMP hTERT group, suggesting that an improved CD4+ response could augment a CTL response. Vaccination was further associated with a reduction of prostate-specific Ag velocity and molecular clearance of circulating micrometastases. Our findings provide a rationale for further development of hTERT-transfected DC vaccines in the treatment of prostate and other cancers.

Original languageEnglish
Pages (from-to)3798-3807
Number of pages10
JournalJournal of Immunology
Volume174
Issue number6
StatePublished - Mar 15 2005
Externally publishedYes

Fingerprint

CD8 Antigens
CD4 Antigens
Telomerase
Dendritic Cells
Lysosome-Associated Membrane Glycoproteins
Prostatic Neoplasms
T-Lymphocytes
Messenger RNA
Vaccination
Vaccines
Intradermal Injections
Neoplasm Micrometastasis
Immunotherapy
Prostate
Neoplasms
Clinical Trials
Therapeutics
Proteins

ASJC Scopus subject areas

  • Immunology

Cite this

Su, Z., Dannull, J., Yang, B. K., Dahm, P., Coleman, D., Yancey, D., ... Vieweg, J. (2005). Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. Journal of Immunology, 174(6), 3798-3807.

Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. / Su, Zhen; Dannull, Jens; Yang, Benjamin K.; Dahm, Philipp; Coleman, Doris; Yancey, Donna; Sichi, Sylvia; Niedzwiecki, Donna; Boczkowski, David; Gilboa, Eli; Vieweg, Johannes.

In: Journal of Immunology, Vol. 174, No. 6, 15.03.2005, p. 3798-3807.

Research output: Contribution to journalArticle

Su, Z, Dannull, J, Yang, BK, Dahm, P, Coleman, D, Yancey, D, Sichi, S, Niedzwiecki, D, Boczkowski, D, Gilboa, E & Vieweg, J 2005, 'Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer', Journal of Immunology, vol. 174, no. 6, pp. 3798-3807.
Su, Zhen ; Dannull, Jens ; Yang, Benjamin K. ; Dahm, Philipp ; Coleman, Doris ; Yancey, Donna ; Sichi, Sylvia ; Niedzwiecki, Donna ; Boczkowski, David ; Gilboa, Eli ; Vieweg, Johannes. / Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. In: Journal of Immunology. 2005 ; Vol. 174, No. 6. pp. 3798-3807.
@article{aafcd12fb5304572b389d7fd59ae19df,
title = "Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer",
abstract = "Telomerase reverse transcriptase (hTERT) represents an attractive target for cancer immunotherapy because hTERT is reactivated in most human tumors. A clinical trial was initiated in which hTERT mRNA-transfected dendritic cells (DC) were administered to 20 patients with metastatic prostate cancer. Nine of these subjects received DC transfected with mRNA encoding a chimeric lysosome-associated membrane protein-1 (LAMP) hTERT protein, allowing for concomitant induction of hTERT-specific CD8+ and CD4+ T cell responses. Treatment was well tolerated. Intense infiltrates of hTERT-specific T cells were noted at intradermal injection sites after repeated vaccination. In 19 of 20 subjects, expansion of hTERT-specific CD8+ T cells was measured in the peripheral blood of study subjects, with 0.9-1.8{\%} of CD8+ T cells exhibiting Ag specificity. Patients immunized with the chimeric LAMP hTERT vaccine developed significantly higher frequencies of hTERT-specific CD4+ T cells than subjects receiving DC transfected with the unmodified hTERT template. Moreover, CTL-mediated killing of hTERT targets was enhanced in the LAMP hTERT group, suggesting that an improved CD4+ response could augment a CTL response. Vaccination was further associated with a reduction of prostate-specific Ag velocity and molecular clearance of circulating micrometastases. Our findings provide a rationale for further development of hTERT-transfected DC vaccines in the treatment of prostate and other cancers.",
author = "Zhen Su and Jens Dannull and Yang, {Benjamin K.} and Philipp Dahm and Doris Coleman and Donna Yancey and Sylvia Sichi and Donna Niedzwiecki and David Boczkowski and Eli Gilboa and Johannes Vieweg",
year = "2005",
month = "3",
day = "15",
language = "English",
volume = "174",
pages = "3798--3807",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "6",

}

TY - JOUR

T1 - Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer

AU - Su, Zhen

AU - Dannull, Jens

AU - Yang, Benjamin K.

AU - Dahm, Philipp

AU - Coleman, Doris

AU - Yancey, Donna

AU - Sichi, Sylvia

AU - Niedzwiecki, Donna

AU - Boczkowski, David

AU - Gilboa, Eli

AU - Vieweg, Johannes

PY - 2005/3/15

Y1 - 2005/3/15

N2 - Telomerase reverse transcriptase (hTERT) represents an attractive target for cancer immunotherapy because hTERT is reactivated in most human tumors. A clinical trial was initiated in which hTERT mRNA-transfected dendritic cells (DC) were administered to 20 patients with metastatic prostate cancer. Nine of these subjects received DC transfected with mRNA encoding a chimeric lysosome-associated membrane protein-1 (LAMP) hTERT protein, allowing for concomitant induction of hTERT-specific CD8+ and CD4+ T cell responses. Treatment was well tolerated. Intense infiltrates of hTERT-specific T cells were noted at intradermal injection sites after repeated vaccination. In 19 of 20 subjects, expansion of hTERT-specific CD8+ T cells was measured in the peripheral blood of study subjects, with 0.9-1.8% of CD8+ T cells exhibiting Ag specificity. Patients immunized with the chimeric LAMP hTERT vaccine developed significantly higher frequencies of hTERT-specific CD4+ T cells than subjects receiving DC transfected with the unmodified hTERT template. Moreover, CTL-mediated killing of hTERT targets was enhanced in the LAMP hTERT group, suggesting that an improved CD4+ response could augment a CTL response. Vaccination was further associated with a reduction of prostate-specific Ag velocity and molecular clearance of circulating micrometastases. Our findings provide a rationale for further development of hTERT-transfected DC vaccines in the treatment of prostate and other cancers.

AB - Telomerase reverse transcriptase (hTERT) represents an attractive target for cancer immunotherapy because hTERT is reactivated in most human tumors. A clinical trial was initiated in which hTERT mRNA-transfected dendritic cells (DC) were administered to 20 patients with metastatic prostate cancer. Nine of these subjects received DC transfected with mRNA encoding a chimeric lysosome-associated membrane protein-1 (LAMP) hTERT protein, allowing for concomitant induction of hTERT-specific CD8+ and CD4+ T cell responses. Treatment was well tolerated. Intense infiltrates of hTERT-specific T cells were noted at intradermal injection sites after repeated vaccination. In 19 of 20 subjects, expansion of hTERT-specific CD8+ T cells was measured in the peripheral blood of study subjects, with 0.9-1.8% of CD8+ T cells exhibiting Ag specificity. Patients immunized with the chimeric LAMP hTERT vaccine developed significantly higher frequencies of hTERT-specific CD4+ T cells than subjects receiving DC transfected with the unmodified hTERT template. Moreover, CTL-mediated killing of hTERT targets was enhanced in the LAMP hTERT group, suggesting that an improved CD4+ response could augment a CTL response. Vaccination was further associated with a reduction of prostate-specific Ag velocity and molecular clearance of circulating micrometastases. Our findings provide a rationale for further development of hTERT-transfected DC vaccines in the treatment of prostate and other cancers.

UR - http://www.scopus.com/inward/record.url?scp=20144364773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144364773&partnerID=8YFLogxK

M3 - Article

VL - 174

SP - 3798

EP - 3807

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 6

ER -